Bharat Bioech ships Covaxin to 11 cities

▴ Bharat Bioech ships Covaxin to 11 cities
Covaxin the inactivated vaccine reaches India cities, though final trial reports are awaited

Bharat Biotech announced a successful air-shipment of Covaxin to 11 cities in India in the early hours of Wednesday. It has also donated 16.5 lakh doses of the Covid vaccine to the Government of India.

The company has expressed deepest gratitude to the nation, all the clinical trial volunteers, and its partners for making this a successful and milestone public-private partnership for the development of India's first Covid-19 vaccine.

After receiving the government purchase order for 55 lakh doses, Bharat Biotech shipped the first batch of the Covid vaccine (each vial containing 20 doses) to Ganavaram, Guwahati, Patna, Delhi, Kurukshetra, Bengaluru, Pune, Bhubaneswar, Jaipur, Chennai and Lucknow. While some shipments have arrived in respective cities, others will be delivered later this evening.

Covaxin is a highly purified and inactivated two-dose SARS-CoV-2 vaccine, manufactured in a Vero cell manufacturing platform with an excellent safety track record of more than 300 million doses. This vaccine by Bharat Biotech is a totally indigenous Covid-19 vaccine developed in collaboration with the Indian Council of Medical Research (ICMR), National Institute of Virology (NIV).

This indigenous, inactivated vaccine has been developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) biocontainment facility, one of its kind in the world. The evaluation of Covaxin has resulted in several unique product characteristics including long-term persistence of immune responses to multiple viral proteins, as opposed to only the spike protein, and has demonstrated broad-spectrum neutralising capability with heterologous SARS-CoV-2 strains, thus potentially reducing or eliminating escape mutants.

This vaccine has also shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and rapid antibody response to future infections. Its most critical characteristic is the demonstrated safety profile, which is significantly lower than several other vaccines with published data. Covaxin is presented in multi-dose vials and can be stored at 2º-8º C.

The product development and clinical trial data so far have generated five publications, which have been submitted to international peer-reviewed journals, four of which have been accepted and will be published soon. The publication of Phase II trial data is undergoing the peer review process.

Tags : #Covaxin #BharatBiotech #InactivatedCoronavirus #BSL-3 #Heterologous #Patna #Delhi #Bengaluru #Pune

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026